论文部分内容阅读
目的探讨对初次复治涂阳肺结核患者采用莫西沙星及利福布丁方案开展超短程治疗的临床疗效及安全性。方法将我院2014年8月～2015年8月收治的初次复治涂阳肺结核患者68例选为研究对象,探讨其临床疗效及安全性。结果治疗后64.7%患者痰菌转阴,26.5%患者无痰,8.8%患者痰菌及痰结核菌培养阳性;行胸部CT检查显示91.2%患者病灶明显吸收,8.8%患者吸收不明显。结论莫西沙星及利福布丁方案对初次复治涂阳肺结核超短程治疗效果较好。
Objective To investigate the clinical efficacy and safety of using moxifloxacin and rifabutin in the first retreatment of smear positive pulmonary tuberculosis patients. Methods 68 cases of primary retreatment smear positive pulmonary tuberculosis admitted from August 2014 to August 2015 in our hospital were selected as research objects to investigate their clinical efficacy and safety. Results After the treatment, 64.7% of the patients had sputum negative, 26.5% of the patients had no sputum, and 8.8% of the patients had positive sputum and sputum TB cultures. Chest CT examination showed that 91.2% of the patients had obvious lesions and 8.8% of the patients did not. Conclusion The moxifloxacin and rifabutin regimens are effective in the treatment of ultra-short-course pulmonary tuberculosis after initial retreatment.